Moving Targets

Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol

(2018) Yu-Xin Xu et al.   ATHEROSCLEROSIS

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate

(2018) Karam M. Kostner et al.   ATHEROSCLEROSIS

Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association

(2018) Sandra B. Dunbar et al.   CIRCULATION

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study

(2018) Matthew Budoff et al.   CLINICAL CARDIOLOGY

APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia

(2018) Joel Schmitz et al.   CURRENT MEDICINAL CHEMISTRY

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

(2018) Shizuya Yamashita et al.   Journal of Clinical Lipidology

INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES

(2018) Veronica J. Alexander et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice

(2018) Ryo Kawakami et al.   PLoS One

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease

(2018) Ekaterina Biterova et al.   Scientific Reports

Lipoprotein(a): the revenant

(2017) Baris Gencer et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

(2017) Christine Landlinger et al.   EUROPEAN HEART JOURNAL

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

(2017) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

(2017) Jerome D. Cohen et al.   Journal of Clinical Lipidology

Current and future pharmacological therapies for NAFLD/NASH

(2017) Yoshio Sumida et al.   JOURNAL OF GASTROENTEROLOGY

AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE −/− mice

(2017) Ang Ma et al.   JOURNAL OF LIPID RESEARCH

Optimizing Cholesterol Treatment in Patients With Muscle Complaints

(2017) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

(2017) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Hypertriglyceridemia and atherosclerosis

(2017) Jia Peng et al.   Lipids in Health and Disease

RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus

(2017) Xue-Hai Liang et al.   MOLECULAR THERAPY

Exome-wide association study of plasma lipids in >300,000 individuals

(2017) Dajiang J Liu et al.   NATURE GENETICS

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

(2017) Christopher P. Cannon et al.   JAMA Cardiology

CRISPR-Cas9 Targeting ofPCSK9in Human Hepatocytes In Vivo—Brief ReportSignificance

(2016) Xiao Wang et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH)

(2016) D. Gaudet et al.   ATHEROSCLEROSIS

Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion

(2016) Lily Jakulj et al.   Cell Metabolism

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease

(2016) Børge G. Nordestgaard   CIRCULATION RESEARCH

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

(2016) Paul D. Thompson et al.   Journal of Clinical Lipidology

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients

(2016) Evan Stein et al.   Journal of Clinical Lipidology

A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE LIVER-SELECTIVE TR-BETA AGONIST VK2809 (MB07811) IN HYPERCHOLESTEROLEMIC SUBJECTS

(2016) Brian Lian et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

Lomitapide and Mipomersen

(2014) Daniel J. Rader et al.   CIRCULATION

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

(2014) Barbara Sjouke et al.   Lancet Diabetes & Endocrinology

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

(2013) John J.P. Kastelein et al.   Journal of Clinical Lipidology

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Discovery and refinement of loci associated with lipid levels

(2013) Cristen J Willer et al.   NATURE GENETICS

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

(2012) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Antisense oligonucleotides for the treatment of dyslipidaemia

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants

(2012) Roeland Huijgen et al.   EUROPEAN HEART JOURNAL

Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users

(2012) Jerome D. Cohen et al.   Journal of Clinical Lipidology

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

(2011) Harold E. Bays et al.   AMERICAN JOURNAL OF CARDIOLOGY

Triglycerides and Cardiovascular Disease

(2011) Michael Miller et al.   CIRCULATION

Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes: ACCORD trial

(2011) R. T. Anderson et al.   DIABETES CARE

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Biological, clinical and population relevance of 95 loci for blood lipids

(2010) Tanya M. Teslovich et al.   NATURE

S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies

(2009) Majken K. Jensen et al.   AMERICAN HEART JOURNAL

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

(2009) Sekar Kathiresan et al.   NATURE GENETICS

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

(2008) Cristen J Willer et al.   NATURE GENETICS